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January 2012302 AbstractsBackground: It is customary to recommend wearing of elastic band
compression or compression stocking after treatment of varicose veins. We
wanted to learn through this study the benefit of wearing elastic compression
after surgical treatment of varicose veins (VVs).
Methods: We have prospectively included all patients operated on for
unilateral VVs, and distributing them into two groups: Group 1: putting on
a class 2 stocking (18mmHg) from the operating day until the postoperative
consultation (approximately 8 days afterwards). Group 2: putting on a class
2 stocking (18 mmHg) from the operating day until the following day (D1)
when it is removed.
Results: One hundred patients were included in the study, in equal
proportion (50) between group 1 and group 2. The study of the demo-
graphic, clinical and hemodynamic characteristics, show no significant dif-
ference between the two groups. All the surgical procedures had been carried
out under tumescent local anesthesia, in short ambulatory. The procedures
carried out were not significantly different between group 1 and group 2,
and had been most frequently phlebectomy with conservation of the reflux-
ing saphenous vein (ASVAL) (46% vs. 48%). The patients all returned to
postoperative consultation (on average 10.0 days on average for group 1 and
9.4 days group 2, nonsignificant: NS) for evaluation. The average pain score
(visual analog scale: VAS) was not significantly different between group 1
and group 2 (0.6 vs. 0.8). The self-evaluation by VAS of the size of
ecchymoses reported an average score without significant difference be-
tween groups 1 and 2 (1.3 vs. 1.2). The circumference of the ankle measured
was not significantly different between the operated limb and the contralat-
eral limb, for group 1 (26.2 cm vs. 25.9 cm) as well as for group 2 (26.2 cm
vs. 26.0 cm). The measurement of the quality of life by the CIVIQ ques-
tionnaire found an average score of 7.00 in group 1 vs. 8.64 in group 2 (NS).
Superficial or deep vein thrombosis was not found in any case. Lastly, 73.3%
of the patients in group 1 and 67.7% of the patients in group 2 (NS) did not
have sick leave, and the average sick leave was, respectively, 2.6 and 2.3 days
in group 1 and 2 (NS).
Conclusions: We found no value of wearing the compression after a
surgical treatment of the varicose veins beyond the 1st postoperative day for
pain, ecchymoses and the quality of life after the procedure. These results
were obtained in the context of a mini-invasive surgery carried out under
tumescent local anesthesia with immediate ambulation.
Contemporary Results Following Saphenopopliteal Transposition For
Chronic Femoral Vein Occlusion
D.M. Coleman, J.E. Rectenwald, F.C. Vandy, T.W. Wakefield, University
of Michigan, Ann Arbor, Mich
Background: Chronic occlusion of the femoral or the proximal popli-
teal vein responsible for venous insufficiency and the constellation of clinical
sequelae that ensue remains a surgical challenge that carries notable patient
morbidity and the threat of potential limb loss. Saphenopopliteal bypass
remains a surgical reconstructive option for select patients that demonstrate
patency of the popliteal vein, greater saphenous vein, saphenofemoral junc-
tion and pelvic veins. We sought to analyze our single-institution experience
with this technique.
Methods: A retrospective review of a single-center experience with
saphenopopliteal transposition was performed. Preoperative risk factors and
indications for intervention (ie: symptomatology including tissue loss) were
identified. Duration of follow-up and end-points including clinical improve-
ment, wound healing, patency and limb loss were assessed. A Kaplan-Meier
analysis for patency was performed.
Results: Seventeen patients underwent a saphenopopliteal bypass for
chronic lower extremity venous obstruction between July, 1988 and August,
2011. Median age at operation was 40 years (range, 23-69 years). There was
a male predominance noted (N12; 71%). All patients suffered from
chronic edema and venous claudication. Six patients (35%) had evidence of
venous ulceration preoperatively. Seven patients (41%) underwent a preced-
ing venous intervention (ie: iliac stenting or venous thrombolysis). Three
patients had a concomitant arteriovenous fistula created to enhance in-flow;
two patients underwent concomitant femoral-femoral venous bypass. Five
patients (29%) experienced hematoma postoperatively that required opera-
tive evacuation; in two patients compression from this hematoma resulted in
early graft occlusion. After a median follow-up of 85months (range, 2-236),
82% of patients experienced symptom improvement or near-complete symp-
tom resolution. Four of the six patients with venous ulceration healed their
wounds (67%). Of the sixteen patients that underwent Duplex follow-up,
primary patency was 68.7% and secondary patency was 75%. (Fig) One
patient required amputation and there were no deaths. This secondary
patency rate exceeds any previously published patency rate.
Conclusions: Saphenopopliteal bypass is indicated for chronic venous
stasis disease secondary to deep venous obstruction at the thigh. This venous
reconstruction option remains a satisfactory and reliable procedure that
produces clinical improvement in a selected group of patients and should be
considered in a contemporary venous surgical practice.
a
viberation Procedure in the Treatment of Chronic Cerebro-Spinal Ve-
ous Insufficiency - Is Chronic Cerebro-Spinal Venous Insufficiency Re-
ated To Brain Congestive Syndrome Rather Than Multiple Sclerosis
.J. Milic, P. Bosnjakovic, S. Vojinovic, Z. Sasa, A. Ilic, D. Stojanov,
. Milojkovic, Clinical Centre Nis, Nis, Serbia
Background: Chronic cerebro-spinal venous insufficiency (CCSVI)
s a term developed to describe compromised flow of blood in the veins
raining the central nervous system. It has been suggested by some
uthors that this condition is related to Multiple Sclerosis (MS). Balloon
ngioplasty and stenting have been proposed as a treatment option for
CSVI in MS. The proposed treatment has been termed ”liberation
rocedure” though the name has been criticized for suggesting unreal-
stic results.
Methods: An open,prospective,single-center study, was performed
n order to determine the efficacy of “Liberation procedure” in the
reatment of different forms of MS (relapsing remitting,secondary pro-
ressive, primary progressive, and progressive relapsing). The evaluation
f patient’s status before the procedure, 6 and 12 months after the
rocedure was performed using: Expanded Disability Status Scale
EDSS); MSFC-Multiple sclerosis functional composite(TIMED 25-
OOT WALK;9-HOLE PEG TEST;PASAT-Paced auditory serial test)
nd SDMT-Symbol digit modalities test. The outcome of the procedure
as also analyzed using: PRO-patient related outcomes, SF-36 question-
aire,EQ-5D (EuroQol) and Functional Assessment of Multiple Sclero-
is (FAMS) quality of life. In order to determine the effects of the
rocedure blood sample from jugular vein was analyzed 24h before the
rocedure and 24h, 72h and 7 days after the procedure (pH and
icarbonate, BE, pCO2 and pO2, K, Na, CRP).
Results:Overall 205 patients completed the study (86 men and 119
omen). Ninety-two patients had relapsing-remitting MS, 103 patients
ad secondary progressive form and 10 patients had primary progressive
S. Avarage patient’s age was 41.21years. The EDSS before the “Lib-
ration procedure” was 5.5021.95 (visual-0.240.71;brainstem-
.061.29; pyramidal-3.11.16;cerebellar-2.00.99; sensory-
.640.72; bowel/bladder- 1.140.87; cerebral 0.871.17). On the
heck-up 6 and 12 months after the procedure the EDSS did not show
Fig.ny statistical significant difference between the pre and post procedural
alues. However, initial benefit of the procedure was seen in almost 70%
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Volume 55, Number 1 Abstracts 303of treated patients. This benefit was impossible to quantify due to the fact
that neurological tools measures quality of changes in different systems
but not the quantity. During the one year follow-up period over 40% of
treated patients developed almost all symptoms that were present before
the procedure. It is interesting that initial benefit was associated with the
improvement in the biochemical parameters from the blood sample
analysis. This brain decongestions after “Liberation” procedure is prob-
ably the reason for relatively fast improvement in clinical signs that we see
in some group of treated patients.
Conclusions: The results obtained in this study suggest that CCSVI is
related to Brain Congestive Syndrome rather than MS indicating that
“Liberation” procedure may improve clinical signs in patients with MS
because of brain decongestion.
Design of a Vein Valve Replacement
D.N. Ku1, P. Midha2, 1Emory School of Medicine, Atlanta, Ga, 2Georgia
Institute of Technology, Atlanta, Ga
Background: Chronic Venous Insufficiency (CVI) is a condition pres-
ent in almost 27% of adults in which an insufficient amount of blood is
pumped back to the heart due to damaged or poorly apposed one-way valves in
the leg veins. Valve repair consists of surgical correction of the malfunctioning
valves to improve their function. This generally requires a lengthy surgery and a
minimum of 4 days in the hospital. Vein transplants have proven to be effective,
however they require finding an intact donor valve, invasive surgery, and
hospitalization. A prosthetic vein valve may not require an invasive surgery,
human donor, or lengthy hospital stay.We describe the design, verification, and
preclinical validation tests of a novel prosthetic vein valve.
Methods: A new valve design is created which is naturally open, and is
impregnated with an anticoagulant compound. Verification tests include
competency, flow resistance, mechanical fatigue, and in vitro thromboge-
nicity tests. CFD analysis is used to quantify the amount of shear rates within
the valve that may induce platelet thrombogenicity. A sheep study has been
initiated to evaluate in vivo performance.
Results: The valve allows for physiologic flow rates of 400-600
mL/min as it poses little resistance to flow. The valve can tolerate
forward flow rates as high as 2800 mL/min. The valve is competent
under physiologic backpressures of 35 to 50 mmHg while maintaining an
acceptable level of reflux less than 40 mL/min. The valve withstands
500,000 cycles of fatigue testing without damage or loss of competency.
The new valve has computed wall shear rates below the threshold value of
4000 s1, which has been found to initiate thrombus formation by
platelet activation and aggregation in cardiovascular implants. This con-
trasts with other artificial values that have computed wall shear rates
exceeding 10,000 s1.
The valve has no measurable thrombogenicity to coagulation or
platelet adhesion with in vitro blood circulation testing in comparison
with alternative biomaterials and designs that occlude under identical
conditions. The valve with a stent can be delivered by catheter with no
migration under back and forward pressures of 100 mmHg. The valida-
tion of the device was done through an animal study in sheep external
jugular veins. In a sheep study, patency was found at 6 weeks, surpassing
many autograft valves.
Conclusions: A new prosthetic valve design shows promise for defin-
itive treatment of venous valvular disorders.
Variables Affecting Healing of Venous Leg Ulcers In a Randomized,
Vehicle-Controlled Trial of Topical Cellular Therapy
W. Marston1, R. Kirsner2, R. Snyder3, T. Lee4, I. Cargill4, H. Slade4,
1University of North Carolina, Chapel Hill, NC, 2University of Miami
LeonardMiller School of Medicine, Miami, Fla, 3Barry University School of
Podiatric Medicine, Miami Shores, Fla, 4Healthpoint Biotherapeutics, Ft.
Worth, Tex
Background: HP802-247 is a cell based therapy under development
for treatment of nonhealing venous leg ulcers. The product consists of
growth-arrested neonatal fibroblasts and keratinocytes, sprayed onto the
wound surface in a self-assembling fibrin matrix. A Phase 2 efficacy trial
involving 35 sites collected data on variables thought to influence response
to treatment.
Methods: 362 subjects were screened to enroll 228 into 5 intervention
groups (low dose biweekly (N46), low dose weekly (N43), high dose
biweekly (N44) high dose weekly (N45), or vehicle control (N50).
Biweekly dosing alternated with application of sprayed matrix control to main-
tain blinding. Treatment plus 4-layer compression bandage was administered
weekly for 12weeks or until healed.Outcomemeasures includeddays towound
closure and proportion of wounds healed after 12 weeks of treatment.
Results: Cell treatment (all groups pooled) was superior to vehicle.
Baseline wound area was significantly associated with days to wound
closure (P  .006) but did not affect the proportion of wounds healed at
12 weeks in a multiple logistic regression model (P  .12). Variables
influencing proportion healed in the model are listed below:able. Variables influencing proportion healed
ariable Range of values P value
ntervention Cells vs vehicle .004
ound duration 6 to 104 weeks .001
ound location Lower calf vs other sites .008
As an independent variable outside the model, baseline bacterial counts
10,000 cfu/gm) of Escherichia, Enterobacter, Enterococcus, Morganella and
seudomonas species, or any-hemolytic Streptococcus, reduced the probability of
losure under either treatment (P.05, Chi square). The effect on relative risk
f failure (wound open)wasmore pronounced in the control group (RR 5.4)
han the cell treated group (RR 1.4). No subject who developed a clinically
vident wound infection closed their wound within 12 weeks. Variables found
o have no influence under the conditions of this study included debridement,
emoglobin A1C, hemoglobin, serum creatinine, prealbumin, albumin, periph-
ral neuropathy, and body weight.
Conclusions: In this study, the variables influencing healing were
nitial wound size, wound duration, wound location, and the addition of
ellular therapy to standard compression. The presence of certain bacteria in
he wound at screening inhibited healing, while an episode of infection
revented healing within the 12 week study time frame. This information
ay be used to predict healing potential of an ulcer at baseline, and in the
esign of future intervention trials.
enous Ulcers’ Prevalence Study in Olmsted County - To Measure the
uccess of the Venous Ulcer Initiative
.L. Gloviczki1, H. Kalsi2, J. Heit2, The AVF Ulcer Initiative Committee
embers: E. Cummings, B. Eklof, D. Gillespie, M. Gloviczki, P. Henke,
. Kistner, F. Lurie, W. Marston, T. O’Donnell, M. Passman, L. Pounds,
. Wakefield, 1American Venous Forum, Rochester, Minn, 2Mayo Clinic,
ochester, Minn
Background: Pacific Vascular Symposium VI and American Venous
orum (AVF) issued a call to reduce venous ulcers by 50% in ten years. A series
f recommendations were formulated. To measure the success of the venous
lcer initiative, the ulcer prevalence has to be evaluated. TheOlmstedCounty in
innesota offers in this regard an exceptional opportunity: practically whole
opulation is included in the Rochester Epidemiological Project.
Methods: Preliminary data for the ulcer prevalence study was obtained
sing 11 ICD-9 codes related to venous ulcer diagnosis and treatment
454.0-2, 459.11-13, 459.31, 459.33, 459.81 and 707.9-10). The number
f venous ulcer cases per year was established from year 1991 to 2010. Each
atient was notified only once.
Further study will focus on patients from two last years. The review of
he medical charts will be performed to confirm the venous origin of ulcers.
he calculated prevalence will be extrapolated to the whole American
opulation taking into consideration demographic structure of the Olmsted
ounty and the entire country.
The study will be repeated after ten years period to measure the impact
f the Ulcer Initiative actions.
Results: Between 1991 and 2009/2010 the estimated prevalence of
enous ulcer per year varied from 0.26% to 1.48% (see Fig). In the same time
he population of the county increased considerably (106,966 in 1990 and
44,248 in 2010). The median age rose from 29 to 34 years for men and
rom 31 to 36 for women.
Conclusions: In this preliminary data the estimated prevalence of
enous ulcers in Olmsted County had some fluctuations between 1991 and
009/2010 with concomitant increase in the median age of the population.
urther study with the review of medical charts will establish the exact
urrent incidence and prevalence and will constitute the basis for global
stimation of the ulcer prevalence in the USA.
